Herpes zoster after recombinant herpes zoster vaccination - Immediate post-RHZ-vaccination evolution of CMI, HMI and lymphocyte count and typing.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521547-20-00

Enrollment

Registered

2025-12-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes Zoster virus prevention

Brief summary

The primary endpoint of the study will be the variations and evolution of quantitative values of the 3 parameters over the 3 weeks study period: VZV-specific CMI and quantification, VZV-specific HMI and quantification and Lymphocyte typing

Interventions

DRUGShingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant

DRUGadjuvanted)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the study will be the variations and evolution of quantitative values of the 3 parameters over the 3 weeks study period: VZV-specific CMI and quantification, VZV-specific HMI and quantification and Lymphocyte typing	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026